Skip to main navigation menu Skip to main content Skip to site footer

Challenges and Learning: First Experience of Photopheresis in a Child with Graft-versus-Host Disease

Desafíos y aprendizaje: primera experiencia de fotoféresis en un niño con enfermedad de injerto contra receptor




Section
Clinic cases

How to Cite
Challenges and Learning: First Experience of Photopheresis in a Child with Graft-versus-Host Disease.
Rev. colomb. hematol. oncol. [Internet]. 2024 Dec. 5 [cited 2025 Jan. 10];11(2):77-83. Disponible en: https://doi.org/10.51643/22562915.685

Doris Alexandra Bula Anichiarico
    Mauricio Chaparro Alzogaray
      Marcela Estupiñán Peñaloza

        Alejandra Calderón Gasca,

        Especialista en Hemato Oncología Pediátrica. Fundación Santa Fe de Bogotá.


        Doris Alexandra Bula Anichiarico,

        Fellow de Hemato Oncología Pediátrica. Instituto Nacional de Cancerología.


        Mauricio Chaparro Alzogaray,

        Especialista en Hemato Oncología Pediátrica y en trasplante de progenitores hematopoyéticos. Hospital de La Misericordia.


        Marcela Estupiñán Peñaloza,

        Especialista en Hemato Oncología Pediátrica y en trasplante de progenitores hematopoyéticos. Hospital de La Misericordia.


        Graft-versus-Host Disease (GVHD) is a serious and common complication following allogeneic hematopoietic stem cell transplants (allo-HSCT), accounting for approximately 25% of post-transplant deaths. Its incidence, which has increased over the past two decades, reaches around 50% in patients undergoing allogeneic hematopoietic progenitor cell transplants. Factors such as patient age, the use of unrelated donors, reduced-intensity regimens, and specific sources of stem cells contribute to this increase. Initial treatment involves corticosteroids and calcineurin inhibitors, but in refractory cases, extracorporeal photopheresis (ECP) emerges as an option. Clinical case: We present the case of a pediatric patient undergoing haploidentical allogeneic hematopoietic progenitor cell transplant for severe aplastic anemia, who subsequently developed severe refractory chronic GVHD, with severe liver, skin and mild lung involvement, who underwent extracorporeal photopheresis sessions as part of the second line of GVHD treatment, with a partial response. Conclusion:  the approach and treatment of GVHD results in the impossibility of a single treatment for all patients with this pathology.


        Article visits 44 | PDF visits 47


        1. Grube M, Holler E, Weber D, Holler B, Herr W, Wolff D. Risk factors and outcome of chronic graft-versus-host disease after allogeneic stem cell transplantation-results from a single-center observational study. Biol Blood Marrow Transplant [Internet]. 2016;22(10):1781-91. Disponible en: http://dx.doi.org/10.1016/j.bbmt.2016.06.020
        2. Arai S, Arora M, Wang T, Spellman SR, He W, Couriel DR, et al. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: A report from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant [Internet]. 2015;21(2):266-74. Disponible en: http://dx.doi.org/10.1016/j.bbmt.2014.10.021
        3. Baird K, Cooke K, Schultz KR. Chronic graft-versus-host disease (GVHD) in children. Pediatr Clin North Am [Internet]. 2010;57(1):297-322. Disponible en: http://dx.doi.org/10.1016/j.pcl.2009.11.003
        4. Haroun E, Agrawal K, Leibovitch J, Kassab J, Zoghbi M, Dutta D, et al. Chronic graft-versus-host disease in pediatric patients: Differences and challenges. Blood Rev [Internet]. 2023;60(101054):101054. Disponible en: http://dx.doi.org/10.1016/j.blre.2023.101054
        5. Choi SW, Levine JE, Ferrara JLM. Pathogenesis and management of graft-versus-host disease. Immunol Allergy Clin North Am [Internet]. 2010;30(1):75-101. Disponible en: http://dx.doi.org/10.1016/j.iac.2009.10.001
        6. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. diagnosis and staging working group report. Biol Blood Marrow Transplant [Internet]. 2005;11(12):945-56. Disponible en: http://dx.doi.org/10.1016/j.bbmt.2005.09.004
        7. Jagasia M, Greinix H, Arora M, Williams K, Wolff D, Cowen E, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. the 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant [Internet]. 2015;21(3):389-401.e1. Disponible en: http://dx.doi.org/10.1016/j.bbmt.2014.12.001
        8. Carreras E, Dufour C, Mohty M, Kröger N, editors. The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies [Internet]. 7th ed. Cham (CH): Springer; 2019. Disponible en http://dx.doi.org/10.1007/978-3-030-02278-5
        9. Defilipp Z, Alousi AM, Pidala JA, Carpenter PA, Onstad LE, Arai S. Non relapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the chronic GVHD consortium Blood Adv. Blood Adv. 2021;5:4278-84. Disponible en: https://doi.org/10.1182/bloodadvances.2021004941
        10. Nygaard M, Wichert S, Berlin G, Toss F. Extracorporeal photopheresis for graft-vs-host disease: A literature review and treatment guidelines proposed by the Nordic ECP Quality Group. Eur J Haematol [Internet]. 2020;104(5):361-75. Disponible en: http://dx.doi.org/10.1111/ejh.13381
        11. Drexler B, Buser A, Infanti L, Stehle G, Halter J, Holbro A. Extracorporeal photopheresis in graft-versus-host disease. Transfus Med Hemother [Internet]. 2020;47(3):214-25. Disponible en: http://dx.doi.org/10.1159/000508169
        12. Calore E, Marson P, Pillon M, Tumino M, Tison T, Mainardi C, et al. Treatment of acute graft-versus-host disease in childhood with extracorporeal photochemotherapy/photopheresis: The padova experience. Biol Blood Marrow Transplant [Internet]. 2015;21(11):1963-72. Disponible en: http://dx.doi.org/10.1016/j.bbmt.2015.07.007
        13. Asensi Cantó P, Sanz Caballer J, Solves Alcaína P, de la Rubia Comos J, Gómez Seguí I. Extracorporeal photopheresis in graft-versus-host disease. Transplant Cell Ther [Internet]. 2023;29(9):556-66. Disponible en: http://dx.doi.org/10.1016/j.jtct.2023.07.001
        14. Pierelli L, Perseghin P, Marchetti M, Messina C, Perotti C, Mazzoni A, et al. Extracorporeal photopheresis for the treatment of acute and chronic graft‐versus‐host disease in adults and children: best practice recommendations from an Italian Society of Hemapheresis and Cell Manipulation (SIdEM) and Italian Group for Bone Marrow Transplantation (GITMO) consensus process. Transfusion [Internet]. 2013;53(10):2340-52. Disponible en: http://dx.doi.org/10.1111/trf.12059
        15. Qayed M, Wang T, Hemmer M, Spellman S, Arora M, Couriel D, et al. Influence of age on acute and chronic GVHD in children undergoing HLA-identical sibling bone marrow transplantation for acute leukemia: Implications for prophylaxis. Biol Blood Marrow Transplant [Internet]. 2018;24(3):521-8. Disponible en: http://dx.doi.org/10.1016/j.bbmt.2017.11.004
        16. Chang Y-J, Wu D-P, Lai Y-R, Liu Q-F, Sun Y-Q, Hu J, et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. J Clin Oncol [Internet]. 2020;38(29):3367-76. Disponible en: http://dx.doi.org/10.1200/JCO.20.00150
        17. Kozlov A, Estrina M, Paina O, Bykova T, Osipova A, Kozhokar P, et al. Extracorporeal photopheresis in children with chronic graft-versus-host disease. Pharmaceuticals (Basel) [Internet]. 2021;14(8):808. Disponible en: http://dx.doi.org/10.3390/ph14080808

        Este portal usa cookies para mejorar su experiencia de usuario. Al utilizar nuestro sitio web, usted acepta nuestra Política de cookies.

        Sistema OJS 3.4.0.7 - Metabiblioteca |